The observed connection between NLRP12 expression and inhibition of β-catenin activation opens opportunities for developing new therapeutic interventions for CRC targeting the NLRP12/STK38/GSK3β signaling axis. The gene discussed is GSK3B; the disease is colorectal carcinoma.